Videos
FEops AI-Enabled Solution Improves Outcomes for Heart Disease Patients
FEops AI-Enabled Solution Improves Outcomes for Heart Disease Patients
Study results reveal a doubling of successful single device deployment and a 25% reduction in radiation and contrast medium usage.
By Michael Barbella, Managing Editor10.12.22
The FEops HEARTguide can help significantly improve left atrial appendage occlusion (LLAO) procedural efficiency and outcomes, according to study results.
The 200 patient PREDICT-LAA prospective, multicenter, randomized controlled trial, led by Prof. Dr. Ole De Backer (Righshospitalet, Denmark) and Dr. Philippe Garot (Institut Cardiovasculaire Paris Sud, France) aimed to assess whether the use of FEops HEARTguide computer simulations based on cardiac CT-imaging can contribute to better preprocedural planning and improved procedural outcomes of percutaneous LAAO procedures with the Abbott Amplatzer Amulet device.
“PREDICT-LAA is the first-ever clinical study proving that Artificial Intelligence (AI)-enabled computational modelling of device-anatomy interaction significantly improves procedural outcomes. We are proud that we have been able to show that the accuracy of device sizing and positioning for LAAO procedures is significantly better when using FEops HEARTguide as compared to standard CT-sizing”, said De Backer, principle investigator of PREDICT-LAA.
In terms of procedural efficiency, the trial results revealed a doubling of successful single device deployment, a 25% reduction of the use of radiation and contrast medium, a 20% reduction of procedural time and procedural success without major complications in 100% of cases in the FEops HEARTguide arm. Procedural outcomes also significantly improved: 40% more complete LAA occlusion with no leak, 60% less retraction of the Amplatzer Amulet disc into the LAA and 80% reduced risk of device-related thrombus.
“These trial results clearly reinforce the value of our pioneering digital twin strategy to alter the course of heart disease,” said Matthieu De Beule, co- founder and CEO of FEops. “We are very proud of the results of the PREDICTLAA trial and I am very grateful for the visionary drive of all study investigators and the excellent support of Abbott as a funder and the entire FEops team for making this happen to advance how physicians access therapy options for patients at risk of stroke due to atrial fibrillation. The trial results support us in our mission to continue to spearhead AI-enabled digital twin solutions that help treating the right heart disease patients with the right technology at the right time.”
The FEops HEARTguide cloud-based procedure planning environment uses digital twin technology to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy—preoperatively. FEops HEARTguide is available in the United States for use in LAAo with WATCHMAN and WATCHMAN FLX; and Amplatzer Amuletand in the European Union, U.K., Canada, and Australia. FEops HEARTguide is available for use in both TAVI and LAAo. FEops HEARTguide has to date been used in more than 6,000 patients in over 300 hospitals in over 25 countries.
Privately held FEops, headquartered in Gent, Belgium, is a digital health scale-up altering the course of heart disease by providing physicians with unique digital tools to treat the right patients with the right technology at the right time. FEops is supported by Valiance Advisors, Capricorn partners, PMV and the European Innovation Council (EIC) accelerator programme. FEops contribution to this project was made possible by the funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 945698.
The 200 patient PREDICT-LAA prospective, multicenter, randomized controlled trial, led by Prof. Dr. Ole De Backer (Righshospitalet, Denmark) and Dr. Philippe Garot (Institut Cardiovasculaire Paris Sud, France) aimed to assess whether the use of FEops HEARTguide computer simulations based on cardiac CT-imaging can contribute to better preprocedural planning and improved procedural outcomes of percutaneous LAAO procedures with the Abbott Amplatzer Amulet device.
“PREDICT-LAA is the first-ever clinical study proving that Artificial Intelligence (AI)-enabled computational modelling of device-anatomy interaction significantly improves procedural outcomes. We are proud that we have been able to show that the accuracy of device sizing and positioning for LAAO procedures is significantly better when using FEops HEARTguide as compared to standard CT-sizing”, said De Backer, principle investigator of PREDICT-LAA.
In terms of procedural efficiency, the trial results revealed a doubling of successful single device deployment, a 25% reduction of the use of radiation and contrast medium, a 20% reduction of procedural time and procedural success without major complications in 100% of cases in the FEops HEARTguide arm. Procedural outcomes also significantly improved: 40% more complete LAA occlusion with no leak, 60% less retraction of the Amplatzer Amulet disc into the LAA and 80% reduced risk of device-related thrombus.
“These trial results clearly reinforce the value of our pioneering digital twin strategy to alter the course of heart disease,” said Matthieu De Beule, co- founder and CEO of FEops. “We are very proud of the results of the PREDICTLAA trial and I am very grateful for the visionary drive of all study investigators and the excellent support of Abbott as a funder and the entire FEops team for making this happen to advance how physicians access therapy options for patients at risk of stroke due to atrial fibrillation. The trial results support us in our mission to continue to spearhead AI-enabled digital twin solutions that help treating the right heart disease patients with the right technology at the right time.”
The FEops HEARTguide cloud-based procedure planning environment uses digital twin technology to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy—preoperatively. FEops HEARTguide is available in the United States for use in LAAo with WATCHMAN and WATCHMAN FLX; and Amplatzer Amuletand in the European Union, U.K., Canada, and Australia. FEops HEARTguide is available for use in both TAVI and LAAo. FEops HEARTguide has to date been used in more than 6,000 patients in over 300 hospitals in over 25 countries.
Privately held FEops, headquartered in Gent, Belgium, is a digital health scale-up altering the course of heart disease by providing physicians with unique digital tools to treat the right patients with the right technology at the right time. FEops is supported by Valiance Advisors, Capricorn partners, PMV and the European Innovation Council (EIC) accelerator programme. FEops contribution to this project was made possible by the funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 945698.
Related Searches:
